<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01519167</url>
  </required_header>
  <id_info>
    <org_study_id>DEX-10-16</org_study_id>
    <nct_id>NCT01519167</nct_id>
  </id_info>
  <brief_title>Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure-Type Sedation</brief_title>
  <official_title>Phase IV, Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure-Type Sedation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospira, now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety of dexmedetomidine in a pediatric
      population requiring non-intubated, spontaneous breathing, moderate to deep sedation (NI-MDS)
      for elective diagnostic or therapeutic procedures, expected to take more than 30 minutes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed to evaluate the safety of a continuous infusion of dexmedetomidine (1
      mcg/kg loading dose with 0.6 mcg/kg/hr initial maintenance dose and titrated between 0.2-1.0
      mcg/kg/hr) administered to subjects requiring non-intubated, spontaneous breathing, moderate
      to deep sedation (NI-MDS) for elective diagnostic or therapeutic procedures that are expected
      to take more than 30 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Who Had Success in Sedation</measure>
    <time_frame>From baseline to end of post-treatment period (approximately 24 hours)</time_frame>
    <description>Success in sedation was defined by a combined endpoint which was the combination of the following:
Subject had adequate level of sedation (University of Michigan Sedation Scale [UMSS] score between 1 to 3 [minimally sedated to deeply sedated] or Neonatal Pain, Agitation and Sedation Scale [N-PASS] score between -5 to -2 [Light sedation]) at least 80% of the time the subject was given the study drug.
Subject had successfully completed the procedure without a need for rescue sedation (Midazolam).
Subject had undergone the procedure without artificial ventilation or intervention to restore baseline or normal hemodynamic status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Not Receiving Rescue Midazolam</measure>
    <time_frame>During the treatment period, up to approximately 24 hours</time_frame>
    <description>Number of subjects who did not receive any rescue midazolam for sedation during the study drug infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Have Undergone Procedures Without Artificial Ventilation or Intervention</measure>
    <time_frame>During the treatment period, up to approximately 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Were Adequately Sedated at Least 80% of Time</measure>
    <time_frame>During the treatment period, up to approximately 24 hours</time_frame>
    <description>Subjects who are adequately sedated (UMSS score of 1 to 3 or NPASS score of -5 to -2) at least 80% of the time sedated with the study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Dose of Rescue Midazolam From Start of Dexmedetomidine Infusion</measure>
    <time_frame>During the treatment period, up to approximately 24 hours</time_frame>
    <description>Kaplan-Meier estimates of time in minutes to first dose of rescue midazolam from onset of study drug infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Midazolam Required for Sedation</measure>
    <time_frame>During the treatment period, up to approximately 24 hours</time_frame>
    <description>Frequency of rescue sedation (midazolam) required to maintain a subject within the target sedation range (UMSS score greater than 1 or N-PASS score less than -2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Fentanyl Use for Analgesia</measure>
    <time_frame>During the treatment period, up to approximately 24 hours</time_frame>
    <description>Frequency of rescue analgesia (fentanyl) required from the start of IV sedation to completion of the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Rescue Sedation (Midazolam)</measure>
    <time_frame>During the treatment period, up to approximately 24 hours</time_frame>
    <description>Total amount of rescue sedation (midazolam) required from the start of IV sedation to completion of the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Rescue Analgesia (Fentanyl)</measure>
    <time_frame>During the treatment period, up to approximately 24 hours</time_frame>
    <description>Total amount of rescue analgesia (fentanyl) required from the start of IV sedation to completion of the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Converted to Alternative Sedation or Anesthetic Therapy Due to Failure of Treatment of Study Drug and Rescue Medication</measure>
    <time_frame>During the treatment period, up to approximately 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Ultrasound</condition>
  <condition>CT Scans</condition>
  <condition>MRIs</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>0.1 - 1.0 mcg/kg/hr IV</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>0.025 - 2 mg/kg IV</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>0.5 - 3 mcg/kg IV</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is ≥28 weeks gestational age and &lt;17 years of age.

             - Preterm subjects ≥28 weeks through &lt;38 weeks, gestational age; (Note: Gestational
             age will be calculated as the time elapsed between the first day of the last menstrual
             period to the day of enrollment. If pregnancy was achieved using assisted reproductive
             technology, gestational age will be calculated by adding 2 weeks to the gestational
             age as calculated above.)

          2. Subject is American Society of Anesthesiologists (ASA) Physical Status I, II or III.

          3. Subject requires non-intubated, spontaneous breathing, moderate to deep sedation
             (NI-MDS) in an operating or procedure room with an an intensivist, anesthesiologist or
             dental anesthesiologist in attendance.

          4. Scheduled for an elective procedure that falls into one of the following three
             populations:

               -  Non-invasive diagnostic/therapeutic procedures (NIDTP): including ultrasound
                  (US), computed tomography (CT) scans, magnetic resonance imaging (MRI), cardiac
                  catheterization, transthoracic echocardiogram (TTE);

               -  Minimally invasive diagnostic/therapeutic procedures (MIDTP): including minimally
                  invasive procedures performed under US or CT guidance (e.g. US or CT-guided solid
                  organ biopsy), and routine myocardial biopsies in cardiac transplant recipients;

               -  Surgical procedures: including small surgical procedures (e.g. excisions,
                  biopsies) and dental procedures (e.g. extractions, pulpectomy, pediatric
                  rehabilitation dental procedures, filings and crowns).

          5. Duration of the procedure is expected to take at least 30 minutes to complete.

          6. If female, subject is non-lactating and is either:

               1. Not of childbearing potential, defined as pre-menarche, or surgically sterile due
                  to bilateral tubal ligation, bilateral oophorectomy or hysterectomy.

               2. Of childbearing potential but is not pregnant at time of baseline and is
                  practicing one of the following methods of birth control: oral or parenteral
                  contraceptives, double-barrier method, vasectomized partner, or abstinence from
                  sexual intercourse.

          7. Subject's parent(s) or legally acceptable representative(s) has/have voluntarily
             signed and dated the informed consent document approved by the Institutional Review
             Board. Assent will be obtained where age-appropriate and according to state
             regulations.

        Exclusion Criteria:

          1. Subjects weight at the time of screening is less than 1000 g.

          2. Subject has received general anesthesia within 7 days prior to study drug
             administration.

          3. Subject has participated in an experimental/investigational drug study within 30 days
             prior to study drug administration.

          4. Subject has been exposed to dexmedetomidine within 48 hours prior to study drug
             administration.

          5. Subject that has been previously enrolled in this study (DEX-10-16).

          6. Subject requires endotracheal intubation or laryngeal mask airway (LMA).

          7. Subject is with neurological conditions that in the opinion of the Investigator will
             preclude reliable assessment of sedation scoring. Examples include, but are not
             limited to the following: cerebral palsy, autism, severe mental retardation, etc.

          8. Subject has central nervous system (CNS) disease with an anticipated potential for
             increased intracranial pressure, an uncontrolled seizure disorder and/or known
             psychiatric illness that could confound a normal response to sedative treatment.

          9. Subject requires epidural or spinal anesthesia.

         10. Subject has received treatment with an alpha-2 agonist or antagonist within 14 days
             prior to study drug administration.

         11. Subject has a known allergy to dexmedetomidine, midazolam or fentanyl.

         12. Subject is requiring cardiac catheterization for the purpose of conducting an
             electrophysiology (EP) evaluation or percutaneous intervention (i.e. angioplasty).

         13. Subject for whom opiates, benzodiazepines, dexmedetomidine or other alpha-2 agonists
             are contraindicated.

         14. Subject has received an IV opioid within one hour, or oral/intramuscular (PO/IM)
             opioid within four hours, prior to the start of study drug administration.

         15. Subject has received any pre-induction medication (ie, ketamine, chloral hydrate,
             benzodiazepines) within 4 hours prior to the start of study drug administration.

         16. Subject has acute myocardial infarction recently diagnosed by confirmatory laboratory
             findings within 6 weeks of screening.

         17. Subject has moderate to severe sleep apnea syndrome.

         18. Subject has oxygen saturation (SpO2) ≤90% at screening or baseline, except for
             patients with known cyanotic heart disease undergoing cardiac catheterization.

         19. Subject has bradycardia immediately before dosing, according to respective age group.

               -  ≥28 weeks to &lt;1 month: Heart Rate (HR) &lt;120 beats per minute (bpm)

               -  1 month to &lt;3 months: HR &lt;100 bpm

               -  3 months to &lt;6 months: HR &lt;90 bpm

               -  6 months to &lt;1 year: HR &lt;80 bpm

               -  1 year to &lt;2 years: HR &lt;70 bpm

               -  2 years to &lt;6 years: HR &lt;60 bpm

               -  6 years to &lt;12 years: HR &lt;55 bpm

               -  12 years to 17 years: HR &lt;50 bpm;

             Note: Subject can be reassessed after 5 minutes

         20. Subject has hypotension immediately before dosing, according to respective age group.

               -  ≥28 weeks to &lt;1 month: &lt;60 mmHg (systolic blood pressure [SBP])

               -  1 month to &lt;12 months: &lt;70 mmHg (SBP)

               -  1 year to &lt;10 years: &lt;70 + (2 X age in years) mmHg (SBP)

               -  10 years to 17 years: &lt;90 mmHg (SBP);

             Note: Subject can be reassessed after 5 minutes

         21. Subject has a presence of second-degree or third-degree heart block at screening or
             baseline. The presence of a temporary or permanent pacemaker will waive this exclusion
             criterion.

         22. Subject has acute febrile illness, with a temperature (core or tympanic) ≥38.0°C.

         23. Subject has any other condition or factor which, in the Investigator's opinion, might
             increase the risk to the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Weeks</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-9070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>00936-5067</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2012</study_first_submitted>
  <study_first_submitted_qc>January 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2012</study_first_posted>
  <results_first_submitted>May 5, 2015</results_first_submitted>
  <results_first_submitted_qc>August 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 14, 2015</results_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The number of subjects enrolled was 91, of that 90 subjects received study drug. The remaining 1 subject not treated due to subject being a screen failure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dose Level 1</title>
          <description>Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr</description>
        </group>
        <group group_id="P2">
          <title>Dose Level 2</title>
          <description>Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Diagnostic/TherapeuticProcedureCompleted</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medical condition changes&amp;deep sedation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Evaluable Population: All subjects who receive any amount of study drug. All safety analyses will be performed on this population.</population>
      <group_list>
        <group group_id="B1">
          <title>Dose Level 1</title>
          <description>Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr</description>
        </group>
        <group group_id="B2">
          <title>Dose Level 2</title>
          <description>Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="89"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.1" lower_limit="0.1" upper_limit="0.1"/>
                    <measurement group_id="B2" value="7.97" lower_limit="0.3" upper_limit="17.3"/>
                    <measurement group_id="B3" value="7.89" lower_limit="0.1" upper_limit="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Had Success in Sedation</title>
        <description>Success in sedation was defined by a combined endpoint which was the combination of the following:
Subject had adequate level of sedation (University of Michigan Sedation Scale [UMSS] score between 1 to 3 [minimally sedated to deeply sedated] or Neonatal Pain, Agitation and Sedation Scale [N-PASS] score between -5 to -2 [Light sedation]) at least 80% of the time the subject was given the study drug.
Subject had successfully completed the procedure without a need for rescue sedation (Midazolam).
Subject had undergone the procedure without artificial ventilation or intervention to restore baseline or normal hemodynamic status</description>
        <time_frame>From baseline to end of post-treatment period (approximately 24 hours)</time_frame>
        <population>Efficacy Evaluable Population (Participants who received study drug infusion for at least 30 minutes and had no major protocol deviations)</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2</title>
            <description>Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Had Success in Sedation</title>
          <description>Success in sedation was defined by a combined endpoint which was the combination of the following:
Subject had adequate level of sedation (University of Michigan Sedation Scale [UMSS] score between 1 to 3 [minimally sedated to deeply sedated] or Neonatal Pain, Agitation and Sedation Scale [N-PASS] score between -5 to -2 [Light sedation]) at least 80% of the time the subject was given the study drug.
Subject had successfully completed the procedure without a need for rescue sedation (Midazolam).
Subject had undergone the procedure without artificial ventilation or intervention to restore baseline or normal hemodynamic status</description>
          <population>Efficacy Evaluable Population (Participants who received study drug infusion for at least 30 minutes and had no major protocol deviations)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NIDTP (n=1, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDTP (n=0, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical procedures (n=0, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Not Receiving Rescue Midazolam</title>
        <description>Number of subjects who did not receive any rescue midazolam for sedation during the study drug infusion.</description>
        <time_frame>During the treatment period, up to approximately 24 hours</time_frame>
        <population>Efficacy Evaluable Population (Participants who received study drug infusion for at least 30 minutes and had no major protocol deviations)</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2</title>
            <description>Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Not Receiving Rescue Midazolam</title>
          <description>Number of subjects who did not receive any rescue midazolam for sedation during the study drug infusion.</description>
          <population>Efficacy Evaluable Population (Participants who received study drug infusion for at least 30 minutes and had no major protocol deviations)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NIDTP (n=1, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDTP (n=0, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical procedures (n=0, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Have Undergone Procedures Without Artificial Ventilation or Intervention</title>
        <time_frame>During the treatment period, up to approximately 24 hours</time_frame>
        <population>Efficacy Evaluable Population (Participants who received study drug infusion for at least 30 minutes and had no major protocol deviations)</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2</title>
            <description>Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Have Undergone Procedures Without Artificial Ventilation or Intervention</title>
          <population>Efficacy Evaluable Population (Participants who received study drug infusion for at least 30 minutes and had no major protocol deviations)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NIDTP (n=1, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDTP (n=0, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical procedures (n=0, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Were Adequately Sedated at Least 80% of Time</title>
        <description>Subjects who are adequately sedated (UMSS score of 1 to 3 or NPASS score of -5 to -2) at least 80% of the time sedated with the study drug</description>
        <time_frame>During the treatment period, up to approximately 24 hours</time_frame>
        <population>Efficacy Evaluable Population (Participants who received study drug infusion for at least 30 minutes and had no major protocol deviations)</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2</title>
            <description>Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Were Adequately Sedated at Least 80% of Time</title>
          <description>Subjects who are adequately sedated (UMSS score of 1 to 3 or NPASS score of -5 to -2) at least 80% of the time sedated with the study drug</description>
          <population>Efficacy Evaluable Population (Participants who received study drug infusion for at least 30 minutes and had no major protocol deviations)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NIDTP (n=1, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDTP (n=0, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical procedures (n=0, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Dose of Rescue Midazolam From Start of Dexmedetomidine Infusion</title>
        <description>Kaplan-Meier estimates of time in minutes to first dose of rescue midazolam from onset of study drug infusion</description>
        <time_frame>During the treatment period, up to approximately 24 hours</time_frame>
        <population>Efficacy Evaluable Population (Participants who received study drug infusion for at least 30 minutes and had no major protocol deviations)</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2</title>
            <description>Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Dose of Rescue Midazolam From Start of Dexmedetomidine Infusion</title>
          <description>Kaplan-Meier estimates of time in minutes to first dose of rescue midazolam from onset of study drug infusion</description>
          <population>Efficacy Evaluable Population (Participants who received study drug infusion for at least 30 minutes and had no major protocol deviations)</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NIDTP (n=1, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There was one subject in this group (n=1) and the subject did not receive rescue midazolam.</measurement>
                    <measurement group_id="O2" value="23.5" lower_limit="16.00" upper_limit="28.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDTP (n=0, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No subjects were in the MIDTP group</measurement>
                    <measurement group_id="O2" value="20.00" lower_limit="17.00" upper_limit="34.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical procedures (n=0, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No subjects were in the surgical procedures group</measurement>
                    <measurement group_id="O2" value="20.00" lower_limit="15.00" upper_limit="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Midazolam Required for Sedation</title>
        <description>Frequency of rescue sedation (midazolam) required to maintain a subject within the target sedation range (UMSS score greater than 1 or N-PASS score less than -2).</description>
        <time_frame>During the treatment period, up to approximately 24 hours</time_frame>
        <population>Number of subjects who received any amount (mg) of rescue midazolam for sedation in efficacy evaluable population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2</title>
            <description>Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Midazolam Required for Sedation</title>
          <description>Frequency of rescue sedation (midazolam) required to maintain a subject within the target sedation range (UMSS score greater than 1 or N-PASS score less than -2).</description>
          <population>Number of subjects who received any amount (mg) of rescue midazolam for sedation in efficacy evaluable population.</population>
          <units>Occurrence</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NIDTP (n=0, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDTP (n=0, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical procedures (n=0, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Fentanyl Use for Analgesia</title>
        <description>Frequency of rescue analgesia (fentanyl) required from the start of IV sedation to completion of the procedure.</description>
        <time_frame>During the treatment period, up to approximately 24 hours</time_frame>
        <population>Number of subjects who received any amount (mg) of rescue fentanyl for analgesia in efficacy evaluable population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2</title>
            <description>Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Fentanyl Use for Analgesia</title>
          <description>Frequency of rescue analgesia (fentanyl) required from the start of IV sedation to completion of the procedure.</description>
          <population>Number of subjects who received any amount (mg) of rescue fentanyl for analgesia in efficacy evaluable population.</population>
          <units>Occurrence</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NIDTP (n=0, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDTP (n=0, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical procedures (n=0, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.50" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Amount of Rescue Sedation (Midazolam)</title>
        <description>Total amount of rescue sedation (midazolam) required from the start of IV sedation to completion of the procedure</description>
        <time_frame>During the treatment period, up to approximately 24 hours</time_frame>
        <population>Number of subjects who received any amount (mg) of rescue midazolam for sedation in efficacy evaluable population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2</title>
            <description>Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Rescue Sedation (Midazolam)</title>
          <description>Total amount of rescue sedation (midazolam) required from the start of IV sedation to completion of the procedure</description>
          <population>Number of subjects who received any amount (mg) of rescue midazolam for sedation in efficacy evaluable population.</population>
          <units>milligram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NIDTP (n=0, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.62" spread="1.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDTP (n=0, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.70" spread="0.767"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical procedures (n=0, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.45" spread="0.907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Amount of Rescue Analgesia (Fentanyl)</title>
        <description>Total amount of rescue analgesia (fentanyl) required from the start of IV sedation to completion of the procedure</description>
        <time_frame>During the treatment period, up to approximately 24 hours</time_frame>
        <population>Number of subjects who received any amount (mg) of rescue fentanyl for analgesia in efficacy evaluable population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2</title>
            <description>Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Rescue Analgesia (Fentanyl)</title>
          <description>Total amount of rescue analgesia (fentanyl) required from the start of IV sedation to completion of the procedure</description>
          <population>Number of subjects who received any amount (mg) of rescue fentanyl for analgesia in efficacy evaluable population.</population>
          <units>microgram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NIDTP (n=0, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="10.83" spread="8.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDTP (n=0, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="61.86" spread="65.740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical procedures (n=0, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="104.83" spread="72.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Converted to Alternative Sedation or Anesthetic Therapy Due to Failure of Treatment of Study Drug and Rescue Medication</title>
        <time_frame>During the treatment period, up to approximately 24 hours</time_frame>
        <population>Efficacy Evaluable Population (Participants who received study drug infusion for at least 30 minutes and had no major protocol deviations)</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2</title>
            <description>Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Converted to Alternative Sedation or Anesthetic Therapy Due to Failure of Treatment of Study Drug and Rescue Medication</title>
          <population>Efficacy Evaluable Population (Participants who received study drug infusion for at least 30 minutes and had no major protocol deviations)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NIDTP (n=1, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDTP (n=0, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical procedures (n=0, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious adverse events from start of study drug administration until 24(±12) hours following study drug discontinuation. Reported serious adverse events from the time the subject signed informed consent until 30 days after study drug discontinuation.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dose Level 1</title>
          <description>Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr</description>
        </group>
        <group group_id="E2">
          <title>Dose Level 2</title>
          <description>Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure diastolic decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Investigator may not submit the results of the study for publication without the prior written consent of Hospira.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marcelo Garcia de Rocha MD, Global Medical Director</name_or_title>
      <organization>Hospira</organization>
      <phone>224-212-4424</phone>
      <email>marcelo.rocha@hospira.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

